Tc 99m ior cea1

Drug Profile

Tc 99m ior cea1

Alternative Names: Ior cea1

Latest Information Update: 14 May 2007

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceuticals
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Solid tumours

Most Recent Events

  • 03 Jul 2001 Preregistration for Solid tumour diagnosis in Latin America (Parenteral)
  • 13 Jun 2000 Clinical data have been added to the pharmacokinetics and Cancer therapeutic trials sections
  • 20 Feb 1996 Launched for Solid tumour diagnosis in Cuba (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top